In a report released yesterday, Charles Rhyee from Cowen & Co. reiterated a Buy rating on Nant Health (NASDAQ: NH), with a price target of $4. The company’s shares closed yesterday at $3.06.
According to TipRanks.com, Rhyee is a 4-star analyst with an average return of 11.5% and a 53.6% success rate. Rhyee covers the Services sector, focusing on stocks such as AmerisourceBergen Corporation, Walgreens Boots Alliance, and Cardinal Health.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Nant Health with a $4 average price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $5.26 and a one-year low of $2.60. Currently, Nant Health has an average volume of 76.55K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
NantHealth, Inc. ooperates as an evidence-based, personalized healthcare company, which provides treatment for critical diseases such as cancer. It is based on personalized healthcare approach that integrates novel diagnostics with large scale, biometric and phenotypic data to track patient outcomes and deliver precision medicine.
